文献速递血栓与止血

地塞米松联合甘草酸苷对比地塞米松治疗新诊断免疫性血小板减少症的多中心随机开放标签2期试验

A multicentre randomized open-label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia.
PubMed 文献 · Br J Haematol · 2026-05-24

本研究纳入基线血小板<30×10^9/L的新诊断初治成人ITP患者,随机1:1接受地塞米松联合甘草酸苷(n=55)或地塞米松(n=56),改良意向治疗分析96例(48 vs 48)。第6个月总缓解率联合组56.25%(27/48)高于单药组31.25%(15/48)(p=0.0231),第14天无差异,联合组缓解持续时间更长,未发生3-5级不良事件或死亡。

要点

  • 联合甘草酸苷第6个月总缓解率56.25% vs 31.25%(p=0.0231)。
  • 第14天总缓解率两组无差异。
  • 联合组缓解持续时间更长,无3-5级不良事件或死亡。

核心结论

  • 地塞米松联合甘草酸苷是新诊断ITP的优化初始治疗。

研究设计与样本

  • 多中心随机开放标签2期试验,纳入≥18岁新诊断初治ITP且基线血小板<30×10^9/L患者。
  • 随机1:1分为地塞米松联合甘草酸苷组(n=55)与地塞米松组(n=56)。
  • 改良意向治疗分析纳入至少接受一剂分配治疗的96例(48 vs 48)。

主要发现

  • 第6个月总缓解率联合组56.25%(27/48)高于单药组31.25%(15/48),p=0.0231。
  • 第14天总缓解率两组无差异。
  • 联合组缓解持续时间更长。
  • 最常见治疗中出现的不良事件为胃肠道反应和焦虑。
  • 未发生3-5级不良事件或死亡。

关键数值与推荐

  • 总缓解定义为血小板≥30×10^9/L、至少较基线翻倍且无出血。

临床怎么用

  • 对新诊断初治成人ITP,可考虑地塞米松联合甘草酸苷作为初始治疗以改善第6个月缓解率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Standard first-line therapy with dexamethasone requires further optimization due to unsatisfying long-term outcomes in patients with primary immune thrombocytopenia (ITP). Previous research suggested that glycyrrhizinate induces platelet responses in ITP murine models. This study aimed to compare the efficacy and safety of dexamethasone plus glycyrrhizinate with dexamethasone in patients with newly diagnosed ITP. Eligible patients aged ≥18 years with newly diagnosed, treatment-naïve ITP who had baseline platelet count of <30 × 109/L were enrolled during routine outpatient visits. Recruited patients were randomly assigned 1:1 to receive either dexamethasone plus glycyrrhizinate (n = 55) or dexamethasone (n = 56). The modified intention-to-treat analysis included 96 patients (48 vs. 48) who received at least one dose of allocated treatments. The primary end-point overall response, defined as a platelet count of ≥30 × 109/L, at least doubling of baseline platelet count and no bleeding, was reached in more patients in combination group [56.25% (27/48)] than that in the monotherapy group [31.25% (15/48)] at month 6 (*p = 0.0231), with a longer duration of response, but not at day 14. The most common treatment-emergent adverse events were gastrointestinal reactions and anxiety. No grade 3-5 adverse events or deaths occurred. Dexamethasone plus glycyrrhizinate was an optimized initial therapy in ITP (NCT05023915).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wang H, Wang R, Yuan C, et al. A multicentre randomized open-label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia. Br J Haematol. 2026. PMID: 42178778. doi:10.1111/bjh.70574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。